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Skeletal Muscle Depletion Predicts
the Prognosis of Patients With
Hepatocellular Carcinoma Treated
With Radiotherapy
Joongyo Lee, Yeona Cho, Sangjoon Park, Jun Won Kim and Ik Jae Lee*
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, South Korea
Background: Sarcopenia is gaining attention as a poor prognostic factor for various
types of malignancies. This study evaluated the prevalence and prognostic significance
of sarcopenia and its association with survival in hepatocellular carcinoma (HCC) patients
who underwent radiotherapy (RT) to the primary site.
Materials and Methods: Between January 2009 and November 2016, 156 patients
with HCC that underwent RT to the liver were retrospectively studied. Sarcopenia was
defined as an L3 skeletal muscle index of <49 cm2/m2 for men and <41 cm2/m2 for
women as proposed by Korean-specific cut-off value. Sarcopenia was identified pre- and
post-RT (within 3 months from the end of RT).
Results: Pre-RT sarcopenia occurred in 99 (63.5%) patients and was significantly
associated with higher levels of protein induced by vitamin K absence or antagonist-II
(PIVKA-II), lower percentage of overweight/obesity (body-mass index), higher percentage
of previous systemic chemotherapy, and lower total RT dose. At a median follow-up of
9.3 months, median overall survival (OS) was significantly lower in patients with pre-RT
sarcopenia than in those without (7.1 vs. 15.3 months, p< 0.001). In multivariate analysis
[reporting hazard ratio (HR): 95% confidence interval (CI)], albumin-bilirubin score (2.35:
1.33–4.17; p = 0.003), total dose (0.44: 0.27–0.71; p = 0.001), and pre-RT sarcopenia
(2.38: 1.53–3.70; p < 0.001) were independent OS prognostic factors. Among patients
without pre-RT sarcopenia, 20 newly developed sarcopenia after RT and showed
significantly lower OS compared to those without sarcopenia after RT (n = 35) (median
14.1 vs. 17.5 months, p= 0.018). Multivariate logistic regression analysis [reporting odds
ratio (OR)] demonstrated older age (310.190; p = 0.007), Child-Pugh classification B or
C (15.239; p = 0.047), higher alpha-fetoprotein (128.486; p = 0.008), higher PIVKA-II
(118.536; p= 0.027), and larger planning target volume (51.310; p= 0.026) as significant
factors for newly developed post-RT sarcopenia.
Conclusion: Newly developed sarcopenia after RT, as well as pre-RT sarcopenia, were
associated with poor survival for HCC patients who underwent RT to the liver. This result
suggests the possibility that early intervention such as nutritional support and exercise
therapies before and during RT could prevent muscle wasting and may be effective in
improving the prognosis of HCC patients.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common
malignancies with poor prognosis, and the incidence of
HCC has been steadily rising (1). With the progress in
the diagnosis and treatment of HCC, local treatment such
as resection, transcatheter arterial chemoembolization
(TACE), transcatheter arterial chemotherapy infusion
(TACI), and radiofrequency ablation (RFA) became the
standard treatment, resulting in great improvement in
survival and disease control. In addition, conventional
radiotherapy (RT) or stereotactic body RT (SBRT) achieved
substantial tumor regression and survival as reported in
various studies (2–5). Despite the development of various
treatment strategies, the prognosis of HCC is still poor, and
several studies are underway to find the prognostic factors to
improve outcome.
Poor general condition, low hepatic functional reserve, and
protein energy malnutrition causing impaired immunity and
dysregulated metabolism lead to poor long-term prognosis of
HCC (6, 7). The concept of cachexia has been commonly used
to describe the general condition of such cancer patients. The
agreed diagnostic criterion for cachexia was weight loss >5%,
or weight loss >2% in individuals already showing depletion
according to current bodyweight and height [body-mass index
(BMI) < 20 kg/m²] or skeletal muscle mass (8). However,
cachexia can sometimes be misdiagnosed because the assessment
of weight change depends on patient’s response during a physical
examination (9). Furthermore, changes in body weight do
not fully reflect body composition change, and weight loss is
uncertain for patients with large tumor, pleural effusion, or
severe body edema (10). Therefore, a more qualified indicator
of this wasting condition is needed to predict the prognosis
of HCC.
Sarcopenia is defined by the loss of skeletal muscle mass,
quality, and strength. The causes of sarcopenia include aging,
disuse (poor performance status), nutritional deficiencies,
advanced organ failure, inflammatory disease, and cancer
treatment-related toxicities (11). Noteworthy is that there
is evidence that sarcopenia is prevalent in cancer patients,
regardless of stage of disease and nutritional status (12)
and it is identified as a poor prognostic factor for various
types of malignancies (13–16). Particularly, sarcopenia
occurs frequently in cases of HCC after treatment (17–19)
and many studies on the association of HCC prognosis
with sarcopenia were performed. These studies have shown
that sarcopenia was an independent predictor of mortality
in patients with HCC following partial hepatectomy,
intra-arterial HCC therapy, or after sorafenib (17–20).
However, few studies have investigated that sarcopenia is
an independent predictor of prognosis in patients receiving RT
for HCC.
In this study, we investigated the prevalence and prognostic
significance of sarcopenia in patients that underwent RT for
HCC. In addition, we also evaluated the associated factors that
induce sarcopenia after RT.
MATERIALS AND METHODS
Patient Selection
The medical records and radiology database at Gangnam
Severance hospital were searched for patients with primary HCC
stage I-IVB (Liver Cancer Study Group of Japan [LCSGJ]) that
underwent RT to the liver from January 2009 to November
2016. HCC was diagnosed based on typical dynamic study
findings of enhanced staining in the early phase and attenuation
in the delayed phase (21). Patients who did not receive RT
directly to the liver or those who did not complete RT were
excluded. We evaluated 156 patients who were eligible for
our study.
Treatment
In this study, the aim of RT was classified as definitive, salvage,
and palliative. Definitive aim meant treating the first diagnosed
HCC for the purpose of complete remission. Salvage aim meant
retreatment if previous local treatment of HCC failed. Palliative
aimwas defined as treatment for symptom control when cure was
difficult to achieve.
Patients were treated with RT alone or concurrent
chemoradiotherapy (CCRT). In the CCRT group, concurrent
hepatic arterial infusion of 5-fluorouracil (5-FU) was delivered
during RT. Most patients received conventional RT (30–70Gy in
10–30 fractions) with 3-dimensional conformal RT (3D-CRT) or
intensity-modulated RT (IMRT), and a small number of patients
received SBRT (36–60Gy in four fractions).
Treatment before RT was classified as surgery, systemic
chemotherapy, or local treatment (TACE or TACI or RFA). All
surgeries were partial hepatectomies, and most of the patients
undergoing systemic chemotherapy received sorafenib regimen.
Definition of Sarcopenia
Sarcopenia was identified at two-time points: pre- and post-
RT. Pre-RT sarcopenia was diagnosed with data from the
simulation computed tomography (CT) prior to RT, while post-
RT sarcopenia was diagnosed with data from the follow-up CT
taken within 3 months from the end of RT.
We retrospectively measured the cross-sectional area of
muscle at the level of the third lumbar vertebra using baseline
CT images. The muscles were quantified within a Hounsfield
unit (HU) range of −29 to +150, and muscle boundaries were
manually corrected as needed (Figure 1) (22, 23). Then, we
calculated the L3 skeletal muscle index (L3-SMI) as follows:
The cross− sectional area of muscle at L3 spine level on CT (cm2)
Height × Height (m2)
Sarcopenia defined by international consensus of cancer cachexia
was <55 cm2/m2 for men and <39 cm2/m2 for women (8).
However, this is based on studies among Westerners, and
different standards are needed for Asians with differences in their
intrinsic muscles. Therefore, we used the Korean-specific cut off
values defined in other studies. Sarcopenia was defined as an
L3-SMI of <49 cm2/m2 for men and <41 cm2/m2 for women
as proposed by Korean-specific cut off values (24).
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FIGURE 1 | Segmented computed tomography (CT) images of patients with (A) and without (B) sarcopenia who had similar body mass indices. Skeletal muscle was
measured using the MIM Vista software (MIM corp., version 6.1, OH, USA).
Data Collection
Demographic and treatment characteristics of individual
patients were obtained from the medical records, including
age at diagnosis, sex, tumor stage, liver enzymes, Child-
Pugh classification, tumor marker, and treatment before
RT. All patients underwent initial and response evaluation
based on computed tomography (CT) or magnetic resonance
imaging (MRI).
Height and weight were recorded at first visit to our
department. The BMI grouping based on the World Health
Organization criteria is as follows: BMI < 18.5 kg/m2
(underweight), BMI 18.5–25 kg/m2 (normal weight), BMI 25–30
kg/m2 (overweight), and BMI ≥ 30 kg/m2 (obesity).
Information was collected on the following variables to
analyze the prognostic factors for overall survival (OS): age;
sex; viral infection (hepatitis B virus, hepatitis C virus); total
dose of RT; RT modality; planning target volume (PTV); CCRT;
Child-Pugh classification (A vs. B + C); HCC stage at the time
of RT; portal vein tumor thrombus; prior treatment (resection,
chemotherapy, TACE or TACI or RFA); alpha-fetoprotein (AFP,
cut off value 20 ng/mL); protein induced by vitamin K absence or
antagonist-II (PIVKA-II, cut off value 40 mAU/mL); serum total
protein (cut off value 6.0 g/dL); serum albumin level (cut off value
3.4 g/dL); albumin-bilirubin (ALBI) grade; and BMI. The ALBI
score was derived from the formula (log10 bilirubin [µmol/L] ×
0.66)+ (albumin [g/L]×−0.0852).
Statistical Analysis
Baseline characteristics of patients with and without sarcopenia
were compared via the Pearson χ2 test for categorical data and
independent t-test for continuous data.
OS was defined as the time from start of RT until death or
last patient contact. OS was analyzed using the Kaplan-Meier
method and log-rank test. Univariate and multivariate analyses
for OS were performed with the Cox proportional hazardsmodel.
Multivariate survival analysis was conducted using the Cox
proportional hazards regression, and variables with a p < 0.10
in univariate analysis were included. The multivariate analysis
for risk factor of post-RT sarcopenia was also performed using
logistic regression analysis.
All p-values lower than 0.05 were considered statistically
significant. Statistical analysis was performed using IBM SPSS,
version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient and Treatment Characteristics
The baseline characteristics of total 156 patients are listed in
Table 1. For all the patients, the median L3-SMI for pre-RT
was 46.4 cm2/m2 (range 29.5–66.6 cm2/m2) in men and 38.4
cm2/m2 (range 26.1–57.5 cm2/m2) in women. According to
Korean-specific cut off standard, 99 patients (63.5%) had pre-RT
sarcopenia; 81 patients (81.8%) weremen and 18 (18.2%) women.
Of the 156 patients, 90 patients had stage IV disease, of whom
21 patients had distant metastasis. Most patients were Child-
Pugh class A (n = 96, 61.5%) and few were Child-Pugh class C
(n= 3, 1.9%). According to the BMI, patients with normal weight
were the most frequent (n = 104, 66.7%), followed by those who
were overweight (n = 41, 26.3%). Pre-RT sarcopenia group had
higher PIVKA-II (p = 0.001), lower serum total protein level
(p = 0.027), lower serum albumin level (p = 0.015), and lower
percentage of overweight/obesity BMI (p < 0.001). Although not
statistically significant, pre-RT sarcopenic patients had poorer
Child-Pugh class and more advanced stage.
Regarding treatment characteristics, 81 patients (51.9%) were
treated with concurrent intra-arterial chemotherapy, and 75
patients (48.1%) were treated with RT alone. Most of the patients
(n = 153, 98.1%) received conventional RT, and only three
patients (1.9%) received SBRT. Median prescribed equivalent
dose in 2Gy fractions, assuming α/β = 10 (EQD210) was
52.1Gy. Compared with the group without pre-RT sarcopenia,
the pre-RT sarcopenia group had a higher percentage of patients
Frontiers in Oncology | www.frontiersin.org 3 October 2019 | Volume 9 | Article 1075
Lee et al. Impact of Sarcopenia on Radiotherapy
TABLE 1 | Characteristics of total patients with HCC and patients with HCC according to the presence of pre-RT sarcopenia.
Total Pre-RT sarcopenia
Non-sarcopenic Sarcopenic p-value
N = 156 % N = 57 % N = 99 %
Age (years) Median 59 57 61 0.592
Range 23–87 34–80 23–87
Sex Male 128 82.1 47 82.5 81 81.8 0.920
Female 28 17.9 10 17.5 18 18.2
Etiology HBV 113 72.4 39 68.4 74 74.7 0.571
HCV 14 9.0 7 12.3 7 7.1
Non-B, non-C 29 18.6 11 19.3 18 18.2
HCC stage I 3 1.9 2 3.5 1 1.0 0.372
II 15 9.6 6 10.5 9 9.1
III 48 30.8 18 31.6 30 30.3
IVA 69 44.2 24 42.1 45 45.5
IVB 21 13.5 7 12.3 14 14.1
Portal vein tumor thrombus Yes 93 59.6 35 61.4 58 58.6 0.730
No 63 40.4 22 38.6 41 41.4
Child-Pugh score A 96 61.5 40 70.1 56 56.6 0.115
B 57 36.5 16 28.1 41 41.4
C 3 1.9 1 1.8 2 2.0
AFP (ng/mL) Median 210.4 50.2 296.9 0.279
Range 1.3–54,000 1.8–54,000 1.3–54,000
PIVKA-II (mAU/mL) Median 1108.0 446.0 2000.0 0.001
Range 4.5–185,072 4.5–51,851 9.0–185,072
Total protein (g/dL) Median 6.8 7.0 6.7 0.027
Range 4.8–9.3 5.4–8.5 4.8–9.3
Albumin (g/dL) Median 3.5 3.6 3.4 0.015
Range 2.4–4.9 2.5–4.8 2.4–4.9
ALBI score Median −2.18 −2.25 −2.14 0.081
Range −3.55 to −0.64 −3.37 to −0.91 −3.55 to −0.64
BMI (kg/m²) Underweight 4 2.6 0 0 4 4.0 0.000
Normal weight 104 66.7 26 45.6 78 78.8
Overweight 41 26.3 25 43.9 16 16.2
Obesity 7 4.5 6 10.5 1 1.0
Previous treatment Surgery 15 9.6 7 12.3 8 8.1 0.392
Chemotherapy 15 9.6 1 1.8 14 14.1 0.011
TACE/TACI/RFA 94 60.3 37 64.9 57 57.6 0.367
None 55 35.3 18 31.6 37 37.4 0.466
RT aim Curative 113 72.4 45 78.9 68 68.7 0.167
Palliative 43 27.6 12 21.1 31 31.3
Treatment scheme RT alone 75 48.1 31 54.4 44 44.4 0.231
CCRT 81 51.9 26 45.6 55 55.6
RT modality 3D-CRT 52 33.3 21 36.8 31 31.3 0.481
IMRT 104 66.7 36 63.2 68 68.7
RT dose Median 52.1 52.9 52.1 0.029
(EQD2, α/β = 10) Range 30.0–125.0 40.0–125.0 30.0–99.2
PTV (cc) Median 735.4 627.21 829.37 0.017
Range 15.0–5851.2 15.0–3347.1 30.3–5,851.2
RT scheme Conventional RT 153 98.1 55 96.5 98 99.0 0.554
SBRT 3 1.9 2 3.5 1 1.0
HCC, Hepatocellular carcinoma; RT, Radiotherapy; HBV, Hepatitis B virus; HCV, Hepatitis C virus; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-
II; ALBI, Albumin-bilirubin; BMI, Body mass index; TACE, Transcatheter arterial chemoembolization; TACI, Transcatheter arterial chemotherapy infusion; RFA, Radiofrequency ablation;
CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy; IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in 2Gy fractions;
PTV, Planning target volume; SBRT, Stereotactic body radiotherapy.
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with previous systemic chemotherapy (p = 0.011), lower total
prescribed dose (p = 0.029), and larger PTV (p = 0.017). Pre-
RT sarcopenic patients had more RT for palliative treatment
than pre-RT non-sarcopenic patients, even though no statistically
significant difference was found.
Analysis of Survival
Over a median follow-up duration of 9.3 months (range 1.2–81.2
months), 125 patients died. Patients in the pre-RT sarcopenia
group showed poorer OS than those in the pre-RT non-
sarcopenia group (median OS: 7.1 months vs. 15.3 months,
p < 0.001; Figure 2).
The evaluation of post-RT sarcopenia was available in 148
patients. Only four patients in pre-RT sarcopenia group had
overcome the sarcopenia after RT. Among the 57 patients who
did not have sarcopenia before RT, 20 developed sarcopenia
after RT (35.1%). Compared to those without sarcopenia after
RT (n= 35), these 20 patients showed significantly lower OS
(median 14.1 vs. 17.5 months, p = 0.018, Figure 3). The
prognosis of these patients was as poor as those with sarcopenia
before RT.
Prognostic Factors for Survival
The results of Cox proportional hazard regression analysis for
OS are shown in Table 2. In univariate analysis, advanced stage
at the time of RT (HR: 2.63; 95% CI: 1.28–5.40; p = 0.009);
Child-Pugh classification B or C (HR: 1.46; 95% CI: 1.02–
2.10; p = 0.041); higher AFP (HR: 1.63; 95% CI: 1.10–2.41;
p = 0.015); lower serum albumin level (HR: 0.51; 95% CI: 0.35–
0.73; p< 0.001); higher ALBI score (HR: 2.01; 95% CI: 1.47–2.75;
p < 0.001); lower total dose of RT (HR: 0.45; 95% CI: 0.31–
0.64; p < 0.001); and larger PTV (HR: 1.02; 95% CI: 1.00–1.04;
p= 0.021) were identified as poor prognostic factors for OS. Pre-
RT sarcopenia (HR: 2.62; 95% CI: 1.76–3.89; p < 0.001) was also
significant for OS.
Then we performed multivariate analysis; ALBI score (HR:
2.35; 95% CI: 1.33–4.17; p = 0.003); total dose [hazard ratio
(HR): 0.44; 95% CI: 0.27–0.71; p= 0.001); and pre-RT sarcopenia
(HR: 2.38; 95% CI: 1.53–3.70; p < 0.001) were identified as
independent prognostic factors for OS.
In addition, univariate and multivariate analyses were
performed in 57 patients without pre-RT sarcopenia. As a result,
lower total dose (HR: 0.46; 95% CI: 0.24–0.89; p = 0.021),
higher BMI (HR: 2.39; 95% CI: 1.22–4.71; p = 0.011), and newly
developed sarcopenia after RT (HR: 2.53; 95% CI: 1.28–5.02;
p= 0.008) significantly affected survival in both univariate and
multivariate analyses.
Risk Factors for Newly Developed
Sarcopenia After RT
We performed logistic regression analysis to investigate the risk
factors associated with patients with newly developed sarcopenia
after RT (Table 3). Older age [odd ratio (OR): 310.19; p =
0.007]; Child-Pugh classification B or C (OR: 15.24; p = 0.047);
higher AFP (OR: 128.49; p = 0.008); higher PIVKA-II (OR:
118.54; p= 0.027); and larger PTV (OR: 51.31; p = 0.026) were
significant factors for newly developed sarcopenia after RT.
FIGURE 2 | Kaplan-Meier curves of overall survival in patients with or without
pre-RT sarcopenia.
FIGURE 3 | Kaplan-Meier curves of overall survival in patients without pre-RT
sarcopenia. Comparing overall survival between patients with newly developed
sarcopenia after receiving RT and patients who still had no sarcopenia after
RT. RT, radiotherapy.
DISCUSSION
We showed that sarcopenia is an independent factor affecting
survival rates in HCC patients who have received RT to liver.
In addition, pre-RT sarcopenia and newly developed sarcopenia
after RT was significantly associated with poor survival. Patients
who were older and had higher PIVKA-II level before treatment
were more likely to develop sarcopenia after RT.
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TABLE 2 | Univariate and multivariate analysis for OS.
Overall survival
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age (<65 vs. ≥65 years) 0.98 (0.66–1.46) 0.92
Sex (Male vs. Female) 0.81 (0.50–1.31) 0.383
Viral infection (No vs. Yes) 1.28 (0.81–2.03) 0.30
HCC stage (I + II vs. III + IV) 2.63 (1.28–5.40) 0.00 1.75 (0.79–3.85) 0.166
Portal vein tumor thrombus (No vs. Yes) 1.19 (0.83–1.72) 0.34
Child-Pugh class (A vs. B + C) 1.46 (1.02–2.10) 0.04 0.95 (0.60–1.52) 0.842
AFP (<20 ng/mL vs. ≥20 ng/mL) 1.63 (1.10–2.41) 0.01 1.03 (0.65–1.64) 0.888
PIVKA-II (<40 mAU/mL vs. ≥40 mAU/mL) 1.37 (0.87–2.14) 0.17
Total protein (<6.0 g/dL vs. ≥6.0 g/dL) 0.73 (0.43–1.26) 0.264
Albumin (<3.4 g/dL vs. ≥3.4 g/dL) 0.51 (0.35–0.73) 0.000 0.98 (0.55–1.75) 0.937
ALBI score 2.01 (1.47–2.75) 0.000 2.35 (1.33–4.17) 0.003
BMI (<25 vs. ≥25 kg/m2) 1.11 (0.78–1.59) 0.548
Prior treatment
Surgery 0.58 (0.31–1.08) 0.084 0.87 (0.44–1.74) 0.698
Chemotherapy 1.63 (0.91–2.93) 0.099 0.87 (0.44–1.74) 0.900
TACE or TACI or RFA 1.13 (0.78–1.63) 0.512
Treatment scheme (RT alone vs. CCRT) 1.09 (0.77–1.55) 0.637
RT modality (3D CRT vs. IMRT + Tomo) 0.73 (0.51–1.06) 0.097 0.96 (0.58–1.58) 0.869
Total dose (EQD2 <52.1Gy vs. ≥52.1Gy) 0.45 (0.31–0.64) 0.000 0.44 (0.27–0.71) 0.001
PTV 1.02 (1.00–1.04) 0.021 1.01 (0.99–1.03) 0.399
Pre-RT sarcopenia (no vs. yes) 2.62 (1.76–3.89) 0.000 2.38 (1.53–3.70) 0.000
Newly developed sarcopenia after RT (No vs. Yes)* 2.16 (1.12–4.16) 0.021 2.53 (1.28–5.02) 0.008
*Univariate and multivariate analysis for overall survival in patients without pre-RT sarcopenia.
OS, overall survival; HR, Hazard ratio; CI, Confidence interval; HCC, Hepatocellular carcinoma; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-II;
ALBI, Albumin-bilirubin; BMI, Body mass index; TACE, Transcatheter arterial chemoembolization; TACI, Transcatheter arterial chemotherapy infusion; RFA, Radiofrequency ablation; RT,
Radiotherapy; CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy; IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in
2Gy fractions; PTV, Planning target volume.
Recently, many hospitals have been using sarcopenia as a
predictor of prognosis in cancer patients instead of cachexia,
which better reflects nutrition and general condition. The
European Working Group on Sarcopenia in the Elderly
recommended the use of the presence of both reduced
muscle mass and muscle function to identify sarcopenia (25).
Methods for measuring muscle mass include measuring the total
skeletal muscle mass using dual energy X-ray absorptiometry
or obtaining L3-SMI through CT. Muscle function can be
determined by measuring gait speed or handgrip strength.
However, muscle function has the disadvantage of a difficult
and subjective measurement, and several studies use only muscle
mass measurement. In our study, we measured the skeletal
muscle mass through CT, since this makes it easy to diagnose pre-
RT sarcopenia, because the simulation CT is always taken for RT.
If sarcopenia is observed on simulation CT performed for RT, we
can expect that the prognosis of RT will be poor.
The hypothesis that liver disease induces sarcopenia has
been reported in several studies. There are several studies
showing that sarcopenia is significantly increased in patients
who undergo surgery, received chemotherapy, or local therapy
in HCC (18–20). Liver cirrhosis also has a similar relationship
(26). Although the mechanism of this association has not
been elucidated yet, low hepatic functional reserve and protein
energy malnutrition due to liver disease may be the main
causes of sarcopenia. In addition, reduced protein synthesis and
degeneration of proteins by pro-inflammatory cytokines released
from tumor cells may lead to a decrease in the amount of skeletal
muscle mass. Our finding, which showed sarcopenia at a lower
serum albumin and total protein level, may be attributed to
protein energy malnutrition, consistent with previous studies
(18–20, 26). However, Child-Pugh classification and ALBI score,
which more accurately reflects liver function, did not differ
between the two (Pre-RT sarcopenic and non-sarcopenic) groups
(Table 1). In addition, higher PIVKA-II level, was presumed to be
related to tumor burden, but the pathophysiological mechanism
is also unknown. An additional biological approach would be
needed to explain this result.
Chemotherapy, which is used for cancer treatment, is
also suggested to induce sarcopenia by decreasing protein
synthesis by expressing molecules (such as Ras, Raf, MEK, and
ER) and decreasing proliferation of muscle-cell by expressing
mTOR (27, 28). Like the observations in those studies, Pre-
RT sarcopenia group had higher percentage of patients who
underwent systemic chemotherapy before receiving RT in
our study. Other studies have also shown that sarcopenia is
significantly more frequent in advanced renal cell carcinoma
or HCC patients with sorafenib, which is consistent with our
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TABLE 3 | Multivariate logistic regression analysis of newly developed sarcopenia after RT.
Risk factor Regression coefficient Standard error Wald χ 2 value P-value Odds ratios (OR) 95% CI of OR
Lower Upper
Age (<65 vs. ≥65 years) 5.708 2.121 7.240 0.007 301.190 4.713 19249.211
Sex (male vs. female) −4.467 2.388 3.498 0.061 0.011 0.000 1.238
Viral infection (No vs. Yes) 3.347 1.833 3.334 0.068 28.428 0.782 1033.409
HCC stage (I + II vs. III + IV) −1.037 2.463 0.177 0.674 0.355 0.003 44.254
Portal vein tumor thrombus (No vs. Yes) 0.369 1.458 0.064 0.801 1.446 0.083 25.206
Child-Pugh class (A vs. B + C) 2.724 1.370 3.951 0.047 15.239 1.039 223.539
AFP (<20 vs. ≥20 ng/mL) 4.856 1.819 7.129 0.008 128.486 3.638 4537.747
PIVKA-II (<40 vs. ≥40 mAU/mL) 4.775 2.164 4.868 0.027 118.536 1.705 8242.149
ALBI score 1.489 1.282 1.349 0.245 4.433 0.359 54.710
NLR (<4 vs. 4≥) −1.586 1.437 1.218 0.270 0.205 0.012 3.422
BMI (<25 vs. ≥25 kg/m2) −1.939 1.445 1.801 0.180 0.144 0.008 2.442
Prior local treatment (No vs. Yes) 0.897 2.010 0.199 0.655 2.452 0.048 125.925
RT aim (curative vs. palliative) −1.497 1.727 0.751 0.386 0.224 0.008 6.612
Treatment scheme (RT alone vs. CCRT) −1.412 1.662 0.722 0.396 0.244 0.009 6.335
RT modality (3D CRT vs. IMRT + Tomo) 2.063 1.634 1.593 0.207 7.866 0.320 193.538
Total dose (EQD2 <52.1 vs. ≥52.1Gy) −1.564 1.593 0.964 0.326 0.209 0.009 4.748
PTV (<500 vs. ≥500 cc) 3.938 1.765 4.979 0.026 51.310 1.614 1630.973
RT, Radiotherapy; OR, Odds ratio; CI, Confidence interval; HCC, Hepatocellular carcinoma; AFP, Alpha-fetoprotein; PIVKA-II, Proteins induced by vitamin K absence or antagonist-II;
ALBI, Albumin-bilirubin; NLR, Neutrophil-lymphocyte ratio; BMI, Body mass index; CCRT, Concurrent chemoradiation therapy; 3D-CRT, 3-Dimensional conformal radiation therapy;
IMRT, Intensity-modulated radiation therapy; EQD2, Equivalent dose in 2Gy fractions; PTV, Planning target volume.
findings (29, 30). However, in multivariate logistic regression
analysis, previous systemic chemotherapy was not a significant
factor, and this might have been due to the small number of
patients who received chemotherapy prior to RT.
In some studies, sarcopenia has been suggested to be due to
decreased appetite, general condition, and dysphagia (31, 32).
In our study, sarcopenic patients have a lower BMI than
non-sarcopenic patients. Because of this result, it may seem
that there is no difference between sarcopenia and cachexia.
However, sarcopenia and cachexia are independent because
only about 4% of sarcopenic patients were underweight status
(BMI < 18.5 kg/m2).
Several studies have also been published regarding the fact
that sarcopenia causes poor prognosis in the treatment of cancer.
Sarcopenia is significantly associated with prognosis of cancer
treatment in colon, breast, lung, head and neck cancer, and HCC
(13–15). Especially in HCC, prognosis is poor when sarcopenia
is present in patients receiving surgery, chemotherapy, and or
local therapy (TACE, TACI, RFA) (18–20). This tendency is
found not only in HCC but also in liver diseases such as
liver cirrhosis, hepatitis, and liver transplantation (26, 33, 34).
Our study also showed that survival was significantly poor
when sarcopenia accompanied HCC. The mechanism by which
sarcopenia causes poor prognosis in cancer treatment is not yet
known. At present, a possible mechanism is that sarcopenia may
reduce muscle strength, resulting in poor physical performance,
which may reduce tolerability for cancer treatment (14). In
addition, another possible mechanism is that as the amount
of stored protein decreases due to sarcopenia, the metabolism
and immunity decrease proportionally to this, leading to a
decrease in antitumor response and an increase in mortality
(35). However, the molecular mechanism of sarcopenia remains
poorly understood, and further studies are needed.
In our study, univariate and multivariate analyses of OS
showed that ALBI score, total irradiated dose, and pre-RT
sarcopenia were significant factors. OS was significantly better
when the total dose was higher than EQD2 52.1Gy (median
dose), which was in line with previous findings (36).
Consistent with the hypothesis that the low hepatic functional
reserve will cause sarcopenia, ALBI score was significantly
associated with survival. Compared to Child-Pugh classification,
which scores clinical measures including encephalopathy, ALBI
only scores objective values (albumin and bilirubin). Therefore,
other studies have recently shown that the ALBI score can be used
to evaluate the liver function more accurately than Child-Pugh
classification (37, 38).
Among those who did not have pre-RT sarcopenia, 20
patients had newly developed sarcopenia after receiving RT.
These 20 patients were significantly older, higher Child-Pugh
classification B or C, higher level of AFP and PIVKA-II, and
larger PTV than in patients who still had no sarcopenia after
RT. Older age effect seems to be accounted for by age-related
degradation of metabolism and RT tolerance. AFP and PIVKA-II
may also be related to tumor burden, but the pathophysiologic
mechanism is still unknown. Child-Pugh classification is a factor
that is related to liver function. The larger the PTV, the greater
the effect on liver function. It is very important to set up
the RT field in these patients because older age, decreased
liver function, and larger tumor burden eventually decrease
the patient’s nutritional status and reduce the muscle mass.
Similarly, the total functional liver volume in sarcopenia patients
is small and should be considered in surgery, when resection
is performed (39). Therefore, from the radiation oncologist’s
point of view, if the patient needs large volume treatment,
there is need to confirm whether these conditions exist in
the patients.
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Patients with sarcopenia prior to RT, and those newly
developing sarcopenia after RT had significantly lower OS than
patients who had no sarcopenia before and after receiving RT.
One possibility is that sarcopenia may occur due to low hepatic
functional reserve induced by progression of HCC, which may
result in lower OS. Therefore, in addition to patients who have
already developed sarcopenia prior to RT, patients at high risk
of sarcopenia after RT—that is those of older age, with Child-
Pugh classification B or C, higher AFP and PIVKA-II, larger
PTV, and poor prognostic factor of HCC—also need intensive
nutritional support during RT to prevent the development of
sarcopenia after treatment. According to the study conducted in
our hospital, repetitive and intensive nutritional counseling is
needed to improve the quality of life and prevent deterioration
of nutritional status in patients with cancer around the head
and neck, thorax, and abdomen receiving RT (40). Nutritional
interventions in HCC are also expected to show good results
in sarcopenia patients. In our prospective study on the effect
of oral supplementation in HCC patients undergoing RT, we
found that serum albumin levels increased significantly in the
group given oral supplementation with branched-chain amino
acid (41). Therefore, oral supplementation in patients receiving
RT for HCC is very important, in terms of nutritional support.
In our hospital, nutritional counseling is given to all patients
regardless of sarcopenia before RT in HCC patients. This may
likely improve survival rate in these patients.
One of the limitations of this study was that because of the
retrospective analysis, not all variables and possible confounders
could be assessed in all patients. In our study, pre-RT sarcopenic
patients group was significantly larger in PTV than the non-
sarcopenic group. Therefore, this result is probably related to the
higher RT dose in non-sarcopenia patients. In Cox regression
analysis to determine the OS-related prognostic factors (Table 2),
RT dose had a significant effect on OS, but not PTV volume. In
patients with low disease extent and good performance status,
the treatment volume would be small and such patients could
be given a high dose. Likewise, patients’ characteristics and
treatment were heterogeneous, suggesting the possibility that
various confounding factors may exist, which is considered a
limitation of retrospective study.
There were also significant differences in previous
chemotherapy, RT dose, serum albumin level, and total protein
level between patients with and without pre-RT sarcopenia. This
is because the degree of disease had varied considerably by the
time the HCC patients reached the point of considering RT.
However, there were no significant differences in indicators of
liver function such as Child-Pugh classification and ALBI score.
Moreover, there were no clinically significant differences between
each of the two groups in Table 1 (Pre-RT sarcopenic and non-
sarcopenic) and Supplementary Table 1 (Newly developed
sarcopenic and sustained non-sarcopenic) characteristics.
Nevertheless, these findings could be due to selection bias
and unmeasured confounders and are considered to be the
limitations of this study. Therefore, from a physician’s point of
view, efforts such as matching based on these factors may help to
reduce the selection bias and unmeasured confounders. However,
the disease status and treatment were too heterogeneous relative
to the number of patients, making matching difficult. In addition,
we did not analyze the treatment after RT, and further analysis
is needed because it may also affect prognosis. Nonetheless,
this study is one of the largest analyses to assess the prognostic
significance of sarcopenia in patients with HCC who received
RT. Also, as far as we know, the strength of this study is that it is
one of the few studies that analyzed the prognostic significance of
sarcopenia in cancer patients receiving RT, especially in patients
with HCC.
CONCLUSION
In conclusion, the findings of this study suggest that sarcopenia
is frequent in patients with HCC, especially in those with lower
liver function, higher tumor markers, and larger PTV; thus, these
patients are more likely to develop sarcopenia after RT. Thus,
the RT field should be carefully determined for these patients
from the point of view of the radiation oncologist. Assessment
of skeletal muscle depletion by CT imaging is an objective tool
useful for diagnosing sarcopenia. In addition, pre-RT sarcopenia
and newly developed sarcopenia after RT, as determined by
simulation CT for RT, was significantly associated with poorer
OS in HCC patients. Early intervention such as nutritional
support and exercise therapies could prevent muscle wasting and
could be effective in improving the prognosis of HCC patients.
Prospective studies are needed to clarify optimum reference
values of sarcopenia for predicting cancer-specific outcomes for
HCC patients.
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